Liquidia Co. (NASDAQ:LQDA) CEO Sells 14,130 Shares

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 14,130 shares of the company’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $191,744.10. Following the transaction, the chief executive officer now directly owns 1,006,420 shares in the company, valued at $13,657,119.40. This represents a 1.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Liquidia Stock Performance

LQDA stock traded up $0.08 on Wednesday, reaching $13.68. The company had a trading volume of 704,101 shares, compared to its average volume of 966,317. The company’s fifty day moving average is $14.79 and its 200 day moving average is $12.72. The company has a market cap of $1.17 billion, a P/E ratio of -8.39 and a beta of 0.23. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.81.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, sell-side analysts predict that Liquidia Co. will post -1.51 earnings per share for the current year.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in LQDA. GAMMA Investing LLC increased its stake in Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after purchasing an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Liquidia during the 4th quarter valued at about $59,000. Summit Investment Advisors Inc. lifted its holdings in shares of Liquidia by 35.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after acquiring an additional 1,719 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in shares of Liquidia in the fourth quarter worth approximately $142,000. Finally, EntryPoint Capital LLC purchased a new stake in Liquidia in the fourth quarter valued at approximately $154,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

LQDA has been the topic of a number of recent analyst reports. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. Wells Fargo & Company started coverage on shares of Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Liquidia in a report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Liquidia has an average rating of “Buy” and a consensus target price of $26.63.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).